Supplementary Results 1 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

• The analysis of tumor tissue and plasma DNA confirmed impactful genetic insights for treatment plans.
• Results indicate that plasma DNA genotyping can reliably inform actionability across various cancer types.
• Detailed findings emphasize the importance of integrating tumor tissue and plasma DNA data for targeted therapies.
• The NCI-MATCH trial provides a framework for understanding the genetic basis of cancer treatment outcomes.

Abstract